Higher sRAGE levels predict mortality in frail older adults with cardiovascular disease

Abstract

Introduction: The evidence that blood levels of the soluble receptor for advanced glycation end products (sRAGE) predict mortality in people with cardiovascular diseases (CVD) is inconsistent. To clarify this matter, we investigated if frailty status influences this association. Methods: We analysed data of 1016 individuals (median age, 75 years) from three population-based European cohorts, enrolled in the FRAILOMIC project. Participants were stratified by history of CVD and frailty status. Mortality was recorded during 8 years of follow-up. Results: In adjusted Cox regression models baseline serum sRAGE was positively associated with an increased risk of mortality in participants with CVD (HR 1.64, 95%CI 1.09-2.49, P=0.019), but not in non-CVD. Within the CVD group, the risk of death was markedly enhanced in the frail subgroup (CVD-F, HR 1.97, 95%CI 1.18- 3.29, P=0.009), compared to the non-frail subgroup (CVD-NF, HR 1.50, 95%CI 0.71- 3.15, P=0.287). Kaplan-Meier analysis showed that the median survival time of CVDF with high sRAGE (>1554 pg/mL) was 2.9 years shorter than that of CVD-F with low sRAGE, whereas no survival difference was seen for CVD-NF. Area under the ROC curve analysis demonstrated that for CVD-F, addition of sRAGE to the prediction model increased its prognostic value. Conclusions: Frailty status influences the relationship between sRAGE and mortality in older adults with CVD. sRAGE could be used as a prognostic marker of mortality for these individuals, particularly if they are also frail.